Free Trial
NYSE:NKGN

NKGen Biotech (NKGN) Stock Price, News & Analysis

NKGen Biotech logo
$0.16 +0.00 (+1.55%)
As of 03/28/2025 03:46 PM Eastern

About NKGen Biotech Stock (NYSE:NKGN)

Key Stats

Today's Range
$0.15
$0.21
50-Day Range
$0.14
$0.84
52-Week Range
$0.10
$2.19
Volume
185,563 shs
Average Volume
1.90 million shs
Market Capitalization
$7.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Remove Ads
Receive NKGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter.

NKGN Stock News Headlines

Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
NKGen Biotech announces administration of first dose of troculeucel
See More Headlines

NKGN Stock Analysis - Frequently Asked Questions

NKGen Biotech's stock was trading at $0.6552 at the beginning of the year. Since then, NKGN shares have decreased by 75.1% and is now trading at $0.1633.
View the best growth stocks for 2025 here
.

Top institutional shareholders of NKGen Biotech include Polar Asset Management Partners Inc. (1.11%), Polar Asset Management Partners Inc. (1.11%), Magnetar Financial LLC (0.60%) and Kepos Capital LP (0.51%). Insiders that own company stock include Paul Y Song and James A Graf.
View institutional ownership trends
.

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI).

Company Calendar

Today
3/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NKGN
Previous Symbol
NYSE:NKGN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-82,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Book Value
($2.68) per share
Price / Book
-0.06

Miscellaneous

Free Float
40,291,000
Market Cap
$7.34 million
Optionable
Not Optionable
Beta
0.45
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NYSE:NKGN) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners